To date, all validated scales (FIB-4, APRI, and Relation AST/ALT) to measure the grade of fibrosis in patients with advanced liver disease caused by other etiologic agents have proved unsatisfactory for assessing fibrosis in patients with chronic hepatitis D. Lutterkort et al. (2017), in a study of 100 HDV-RNA-positive genotype 1 patients, developed a new model to evaluate fibrosis in patients with Delta hepatitis based on levels of cholinesterase, albumin, and gamma-glutamyl transferase as well as the age of the patient. Here, GPT is linked to liver disorder.